HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $51 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.
June 28, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $51.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $51 indicates that the firm believes the stock has potential for growth, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100